The latest announcement is out from Chemomab Therapeutics ( (CMMB) ).
Chemomab Therapeutics announced its year-end and fourth-quarter 2024 financial results and provided a corporate update on March 3, 2025. The company completed a successful FDA End-of-Phase 2 meeting for its lead product candidate, nebokitug, following positive results from the Phase 2 SPRING trial in PSC. The FDA has aligned with Chemomab on a streamlined pathway to potential regulatory approval, which could make nebokitug the first FDA-approved treatment for PSC. The company is preparing for a pivotal Phase 3 trial and is in discussions with potential strategic partners, highlighting the significant interest in nebokitug’s promising clinical data.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet needs. The company’s primary product candidate is nebokitug (CM-101), which is being developed for the treatment of Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.
YTD Price Performance: -21.13%
Average Trading Volume: 362,865
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $31.68M
For an in-depth examination of CMMB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com